DBP International AB: Canadian patent for Temodex / SI-053 is granted
Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, January 9[th] 2024, received information of the approval of a Canadian patent application concerning the company's front-line product Temodex / SI-053. Patent approval provides protection for the technology and the product in Canada until at least 2036. "This is an important milestone in the development of SI-053 to get product patented and this is very good news for the company especially now prior starting clinical trials”, comments Igor Lokot, CEO of DBP. – “We also have